Goetz Kathleen 4

What Happened Kathleen Goetz, a director of Aurinia Pharmaceuticals Inc. (AUPH), received a grant of 23,931 derivative awards on June 4, 2026. The Form 4 lists the acquisition price as $0.00 and a reported value of $0, indicating these were granted stock-option awards rather than a cash purchase. This is an award/grant (A) — not a sale — and is commonly part of director compensation.

Key Details

• Transaction date: 2026-06-04; filing date (Form 4): 2026-06-08 (filed within required period).
• Grant size: 23,931 derivative awards (listed at $0.00 per share; reported value $0).
• Shares owned after transaction: Not specified on the provided transaction summary of this Form 4.
• Footnote: The options shall vest one year from the date of grant.
• Transaction code: A (award/grant). No 10b5-1 plan, tax withholding, or gift notation reported.

Context This filing documents an option award to a director as part of compensation; it does not reflect an immediate purchase or sale of shares. The options vest after one year — exercise terms (exercise price, expiration) are not shown here — and there is no indication the options were exercised or sold. Grants to directors are common and are primarily a compensation/retention signal rather than a direct bullish or bearish trade by the insider.